Daré Bioscience (Cerulean Pharma) ^{Priced, Nasdaq: DARE}

Developing targeted therapies for kidney, ovarian and other cancers.

Industry: Health Care

First Day Return: -2.1%

DARE

Developing targeted therapies for kidney, ovarian and other cancers.

IPO News for Daré Bioscience (Cerulean Pharma)

Cerulean Pharma prices IPO at $7, well below the $11 to $13 range 04/10/14
16 US IPOs planned for the week of Apr 7 04/07/14
Cancer biotech Cerulean Pharma sets terms for $60 million IPO 03/31/14

IPO Data
IPO Date	04/09/2014
Offer Price	IPO Intelligence Only
Price Range	IPO Intelligence Only
Offer Shares (mm)	IPO Intelligence Only
Deal Size ($mm)	$60
Lock-Up Date	IPO Intelligence Only
Street Research	IPO Intelligence Only

Underwriters
IPO Intelligence Only

Company Data
Headquarters	Cambridge, MA, United States
Founded	2005
Employees at IPO	21
Website www.ceruleanrx.com

IPO News for Daré Bioscience (Cerulean Pharma)

Cerulean Pharma prices IPO at $7, well below the $11 to $13 range 04/10/14
16 US IPOs planned for the week of Apr 7 04/07/14
Cancer biotech Cerulean Pharma sets terms for $60 million IPO 03/31/14

Daré Bioscience (Cerulean Pharma) (DARE) Performance